NRX Pharmaceuticals (NRXP) Cash from Operations (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Cash from Operations data on file, last reported at 4300000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 23.56% year-over-year to 4300000.0 in Q1 2026; TTM through Mar 2026 was 14920000.0, a 42.83% decrease from a year earlier, with the FY2025 full-year figure at 14100000.0, down 32.56% from the prior year.
• Cash from Operations for Q1 2026 stood at 4300000.0, down from 3701000.0 in the prior quarter.
• Over the last five years, Cash from Operations for NRXP reached as high as 2098000.0 in Q4 2024 and fell as low as 14791000.0 in Q2 2022.
• Historically, Cash from Operations has averaged 5320529.41 across 5 years, with a median of 4028000.0 in 2025.
• Across the five-year window, Cash from Operations sank 244.28% in 2022 and soared 67.2% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 8318000.0 in 2022, then jumped by 61.63% to 3192000.0 in 2023, then jumped by 34.27% to 2098000.0 in 2024, then sank by 76.41% to 3701000.0 in 2025, then retreated by 16.18% to 4300000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 4300000.0 in Q1 2026, 3701000.0 in Q4 2025, and 2891000.0 in Q3 2025.